Atherosclerosis is a major contributor to cardiovascular diseases which is one of the leading causes of morbidity and mortality worldwide. Inflammation is not only the key indication of atherosclerosis but also drives the whole disease progression. Therefore, anti-inflammation has been regarded as a promising strategy for atherosclerosis treatment. drugs are lack of specific targeting capability toward the inflammatory sites and show poor half-life, which not merely compromise their therapeutic efficacy but also result in side effects. M2 phenotype macrophages secrete anti-inflammatory cytokines, implying the anti-inflammation therapy effect of M2 macrophages-derived Extracellular Vesicles (M2 Evs). Herein, we molecularly engineer the M2 Evs to endow them with inflammation tropism and intrinsic biosynthesis functionality for effective targeting and treatment of atherosclerosis. The M2 Evs collected from M2 macrophages are further electroporated with an FDA-approved hexyl 5-aminolevulinate hydrochloride to obtain HAL-containing M2 Evs. These Extracellular Vesicles would be promising for the treatment of atherosclerosis.
Learning Objectives:
Upon completion, participants will be able to define the Extracellular Vesicles.
Upon completion, participants will be able to develop a new concept for Extracellular Vesicles.
Upon completion, participant will be able to conduct a experiments plan
